Literature DB >> 8616860

Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells.

O W Press1, D Shan, J Howell-Clark, J Eary, F R Appelbaum, D Matthews, D J King, A M Haines, P Hamann, L Hinman, D Shochat, I D Bernstein.   

Abstract

Radiolabeled antibodies have produced encouraging remissions in patients with chemotherapy-resistant hematological malignancies; however, the selection of therapeutic radionuclides for clinical trials remains controversial. In this study, we compared the internalization, lysosomal targeting, metabolism, and cellular retention of radiolabeled murine and humanized monoclonal antibodies targeting the CD33 antigen (monoclonal antibodies mP67 and hP67, respectively) on myeloid leukemia cell lines (HEL and HL-60) and of anti-carcinoma antibodies (monoclonal antibodies hCTM01 and hA33) targeting breast cancer and colorectal carcinoma cell lines (MCF7 and Colo 205, respectively). Each antibody was labeled with 125I (by the IodoGen method) and with 111In and 90Y using macrocyclic chelation technology. Targeted tumor cells were analyzed for retention and metabolism of radioimmunoconjugates using cellular-radioimmunoassays, Percoll gradient fractionation of cell organelles, SDS-PAGE, and TLC of cell lysates and culture supernatants. Our results suggest that antibodies are routed to lysosomes after endocytosis, where they are proteolytically degraded. [125I]monoiodotyrosine is rapidly excreted from cells after lysosomal catabolism of antibodies radioiodinated by conventional methods, whereas small molecular weight 111In and 90Y catabolites remain trapped in lysosomes. As a consequence of the differential disposition of small molecular weight catabolites, 111In and 90Y conjugates displayed superior retention of radioactivity compared with 125I conjugates when tumor cells were targeted using rapidly internalizing antibody-antigen systems (e.g., hP67 with HEL cells and hCTM01 with MCF7 cells). When tumor cells were targeted using antibody-antigen systems exhibiting slow rates of endocytosis (e.g., hP67 on HL-60 cells and hA33 on Colo 205 cells), little differences in cellular retention of radioactivity was observed, regardless of whether 125I, 111In, or 90Y was used.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8616860

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

Review 1.  Radioimmunotherapy in mantle cell lymphoma.

Authors:  Alan P Skarbnik; Mitchell R Smith
Journal:  Best Pract Res Clin Haematol       Date:  2012-05-09       Impact factor: 3.020

2.  Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands.

Authors:  Marc Hens; Ganesan Vaidyanathan; Phil Welsh; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2009-02       Impact factor: 2.408

3.  Development of a radioiodinated apoptosis-inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies.

Authors:  E W Duiker; E C F Dijkers; H Lambers Heerspink; S de Jong; A G J van der Zee; P L Jager; J G W Kosterink; E G E de Vries; M N Lub-de Hooge
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

4.  The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily.

Authors:  J K Heath; S J White; C N Johnstone; B Catimel; R J Simpson; R L Moritz; G F Tu; H Ji; R H Whitehead; L C Groenen; A M Scott; G Ritter; L Cohen; S Welt; L J Old; E C Nice; A W Burgess
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

Review 5.  Radioimmunotherapy of human tumours.

Authors:  Steven M Larson; Jorge A Carrasquillo; Nai-Kong V Cheung; Oliver W Press
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

6.  Quantification of IgG monoclonal antibody clearance in tissues.

Authors:  Miro J Eigenmann; Ludivine Fronton; Hans Peter Grimm; Michael B Otteneder; Ben-Fillippo Krippendorff
Journal:  MAbs       Date:  2017-06-14       Impact factor: 5.857

7.  A mechanistic compartmental model for total antibody uptake in tumors.

Authors:  Greg M Thurber; K Dane Wittrup
Journal:  J Theor Biol       Date:  2012-09-06       Impact factor: 2.691

8.  Beta-irradiation used for systemic radioimmunotherapy induces apoptosis and activates apoptosis pathways in leukaemia cells.

Authors:  Claudia Friesen; Annelie Lubatschofski; Jörg Kotzerke; Inga Buchmann; Sven N Reske; Klaus-Michael Debatin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-06-26       Impact factor: 9.236

Review 9.  Radioimmunotherapy-based conditioning regimens for stem cell transplantation.

Authors:  Michelle M Zhang; Ajay K Gopal
Journal:  Semin Hematol       Date:  2008-04       Impact factor: 3.851

Review 10.  Advances in the treatment of hematologic malignancies using immunoconjugates.

Authors:  Maria Corinna Palanca-Wessels; Oliver W Press
Journal:  Blood       Date:  2014-02-27       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.